Manufacturing AAV with Trisk
We have spent several years developing solutions at the interface of biology, engineering and control software for manufacturing biologics – starting with AAV.
We manufacture AAV with fully scalable processes that are straightforward to tech transfer: suspension HEK293 cells, triple transfection, purified with a minimum of two-stages of chromatography, and formulated using TFF. We use no ultracentrifugation.
We are set-up to make small batches (~2e13vg) and large batches (~2e14vg) of AAV for use in pre-clinical studies. On request (depending on capacity), we can conduct manufacturability studies and do bespoke process development work.
We are particularly strong in chromatography development, high-throughput upstream optimization, in-process analytics, and formulation development. We have leveraged this expertise to purify novel capsid variants, self-complementary and bicistronic transgenes, and deliver exceptional empty/full ratios according to client requirements.
Our long-term goal is to accelerate the development of AAV-based gene therapies in the clinic, relying on deep process expertise and the deployment of custom automated hardware for biologics manufacturing.